Pembrolizumab with chemoradiotherapy is approved by the USFDA for FIGO 2014 Stage III-IVA cervical cancer
The Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in combination with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer on January 12, 2024.A study called KEYNOTE-A18 (NCT..
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial cancer
As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda, Merck) for people who have locally advanced or metastatic urothelial c..
Belzutifan is approved by USFDA for advanced renal cell carcinoma
The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously received a programmed death recepto..
Pirtobrutinib is approved by the USFDA for chronic lymphocytic leukemia and small lymphocytic lymphoma
The Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) on December 1, 2023, for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have u..
Nirogacestat is approved by the USFDA for desmoid tumors
The Food and Drug Administration authorized nirogacestat (OGSIVEO, SpringWorks Therapeutics, Inc.) on November 27, 2023, for adult patients with advancing desmoid tumors needing systemic treatment. This is the initial authorized ..
Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone specific prior treatments.Efficac..
Enzalutamide is approved by the USFDA for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence.The Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, I..
Capivasertib with fulvestrant is approved by the USFDA for breast cancer treatment
Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for adult patients with hormone receptor (HR)-positive, human epidermal gro..
Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma
The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the initial treatment of adults with ..
Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2023.This FDA approval is the f..